Breaking News Instant updates and real-time market news.

MRNA

Moderna

$20.83

-0.62 (-2.89%)

, AZN

AstraZeneca

$40.45

-0.47 (-1.15%)

05:32
02/20/19
02/20
05:32
02/20/19
05:32

Moderna announces publication of Phase 1a/b study in Nature Communications

Moderna (MRNA) announced the publication of a Phase 1a/b study in Nature Communications showing the potential of mRNA encoding for vascular endothelial growth factor A, or VEGF-A, as a regenerative therapeutic. This approach aims to stimulate the growth of new blood vessels, also known as angiogenesis, to improve blood flow in tissues where it is otherwise restricted. The Phase 1a/b study, conducted with AstraZeneca (AZN), was a randomized, double-blind, placebo-controlled study in Europe of men with type 2 diabetes mellitus. The VEGF-A mRNA was delivered in a saline solution and was administered by intradermal injection into forearm skin in single ascending doses. The trial met its primary objectives of describing safety and tolerability and secondary objectives of protein production and changes in local blood flow post injection. "I believe this is an important milestone in the field of mRNA therapeutics as it starts to address many questions regarding the safety and delivery of mRNA to human tissues, the duration and level of the protein that can be expressed and the ability of the technology to have a physiologic, measurable function over a prolonged period of time," said Kenneth Chien, M.D., Ph.D., a professor in the Department of Cell and Molecular Biology and the Integrated Cardio Metabolic Center at the Karolinska Institute in Stockholm, a Moderna scientific co-founder and co-author on the paper. "Based on these early data, this approach may provide benefit to patients where proper blood flow is compromised in areas such as heart disease and diabetes as well as for other vascular complications."

MRNA

Moderna

$20.83

-0.62 (-2.89%)

AZN

AstraZeneca

$40.45

-0.47 (-1.15%)

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 04

    Mar

  • 17

    Apr

MRNA Moderna
$20.83

-0.62 (-2.89%)

01/08/19
PIPR
01/08/19
NO CHANGE
PIPR
Piper Jaffray sees Moderna clinical data driving value in 2019
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $24 price target on Moderna, which he calls "the leading developer of messenger RNA therapeutics." The analyst noted that Moderna ended 2018 with cash of around $1.7B, and said he is looking for clinical data and progress to drive value in 2019.
01/22/19
PIPR
01/22/19
NO CHANGE
Target $24
PIPR
Overweight
Translate clinical hold has no read-through to Moderna, says Piper Jaffray
Moderna's (MRNA) messenger RNA competitor Translate Bio (TBIO) announced this morning that the FDA placed a clinical hold on its Investigational New Drug Application for MRT5201 to treat ornithine transcarbamylase deficiency, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Translate Bio also had a prior clinical IND hold on MRT5005 for cystic fibrosis due to manufacturing issues, adds the analyst. Tenthoff does not see read-through to Moderna's mRNA platform and pipeline from the news. The FDA accepted the company's IND for mRNA-3704 to treat orphan disease methylmalonic acidemia, and the Phase I/II study will begin soon, says the analyst. He reiterates an Overweight rating on Moderna with a $24 price target. The stock in midday trading is down 3% to $16.15.
02/04/19
PIPR
02/04/19
NO CHANGE
Target $24
PIPR
Overweight
Piper a buyer of Moderna ahead of Phase 1 mRNA-1944 data
Piper Jaffray analyst Edward Tenthoff is a buyer of Moderna ahead of the Phase I data on mRNA-1944 chikungunya virus antibody in the first half of 2019. While the analyst ascribes no value for mRNA-1944 itself, he believes these data will have important read-through to Moderna's emerging Orphan Disease pipeline. mRNA-1944 is Moderna's first systemic secreted mRNA therapeutic and will validate mRNA-3704 for methylmalonic acidemia, mRNA-3927 for propionic acidemi, mRNA-3283 for phenylketonuria, mRNA-3630 for Fabry's disease and several as yet undisclosed orphan disease programs, Tenthoff tells investors in a research note. The analyst keeps an Overweight rating on Moderna with a $24 price target.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $24
PIPR
Overweight
Piper says Moderna mRNA-1944 data has important read-through to rest of pipeline
After Moderna announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944, Piper Jaffray analyst Edward Tenthoff said he sees an important read-through from this data, expected in the first half of 2019, to the rest of Moderna's orphan disease pipeline. The analyst, who thinks mRNA technology is ideally suited to address short-comings of Enzyme Replacement Therapy, keeps an Overweight rating and $24 price target on Moderna shares.
AZN AstraZeneca
$40.45

-0.47 (-1.15%)

12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
02/05/19
EXAN
02/05/19
INITIATION
EXAN
Outperform
AstraZeneca initiated with an Outperform at Exane BNP Paribas
02/05/19
02/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AIG (AIG) initiated with a Neutral at Credit Suisse. 2. Box (BOX) initiated with a Buy at Goldman Sachs. 3. Rocket Pharmaceuticals (RCKT) initiated with an Outperform at Oppenheimer. 4. AstraZeneca (AZN) initiated with an Outperform at Exane BNP Paribas. 5. MercadoLibre (MELI) resumed with a Buy at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

01:50
09/19/19
09/19
01:50
09/19/19
01:50
General news
Asian Market Wrap »

Asian Market Wrap: Asian…

01:40
09/19/19
09/19
01:40
09/19/19
01:40
General news
Norges Bank decision could go either way. »

Norges Bank decision…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. initial claims preview »

U.S. initial claims…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. Philly Fed preview »

U.S. Philly Fed preview:…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. existing home sales preview »

U.S. existing home sales…

01:15
09/19/19
09/19
01:15
09/19/19
01:15
General news
BoJ left policy on hold »

BoJ left policy on hold…

AKAM

Akamai

$90.95

-0.13 (-0.14%)

21:13
09/18/19
09/18
21:13
09/18/19
21:13
Downgrade
Akamai rating change at KeyBanc »

Akamai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

DB

Deutsche Bank

$8.06

-0.125 (-1.53%)

20:32
09/18/19
09/18
20:32
09/18/19
20:32
Hot Stocks
Deutsche Bank lowers prime lending rate to 5.00% from 5.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$9.70

0.33 (3.52%)

20:31
09/18/19
09/18
20:31
09/18/19
20:31
Syndicate
Provention Bio 5M share Spot Secondary priced at $8.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 19

    Sep

DRI

Darden

$127.40

1.31 (1.04%)

20:25
09/18/19
09/18
20:25
09/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

19:48
09/18/19
09/18
19:48
09/18/19
19:48
Syndicate
Exagen 3.6M share IPO priced at $14.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PING

Ping Identity

$0.00

(0.00%)

19:35
09/18/19
09/18
19:35
09/18/19
19:35
Syndicate
Ping Identity 12.5M share IPO priced at $15.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CBS

CBS

$43.38

0.08 (0.18%)

, T

AT&T

$36.77

-0.39 (-1.05%)

19:04
09/18/19
09/18
19:04
09/18/19
19:04
Periodicals
Viacom, CBS, WarnerMedia pull e-cigarette ads from networks, CNBC says »

CBS (CBS),…

CBS

CBS

$43.38

0.08 (0.18%)

T

AT&T

$36.77

-0.39 (-1.05%)

VIA

Viacom

$27.94

-0.06 (-0.21%)

VIAB

Viacom

$25.77

0.02 (0.08%)

BTI

British American Tobacco

$36.90

0.06 (0.16%)

MO

Altria Group

$40.84

-0.47 (-1.14%)

PM

Philip Morris

$71.58

-0.4 (-0.56%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

CRON

Cronos Group

$10.96

-0.205 (-1.84%)

18:57
09/18/19
09/18
18:57
09/18/19
18:57
Hot Stocks
Cronos Group CEO: We focus on supply and the consumer »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

, SVRA

Savara

$2.49

-0.14 (-5.32%)

18:46
09/18/19
09/18
18:46
09/18/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

SVRA

Savara

$2.49

-0.14 (-5.32%)

CBPO

China Biologic

$103.19

0.37 (0.36%)

NCR

NCR Corp.

$33.62

0.77 (2.34%)

MSFT

Microsoft

$138.53

1.13 (0.82%)

TNDM

TNDM

X

U.S. Steel

$12.45

-0.51 (-3.94%)

PRVB

Provention Bio

$9.70

0.33 (3.52%)

PAA

Plains All American

$21.87

-0.315 (-1.42%)

COST

Costco

$292.47

0.96 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 05

    Nov

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

TECD

Tech Data

$103.32

-0.59 (-0.57%)

18:41
09/18/19
09/18
18:41
09/18/19
18:41
Hot Stocks
Tech Data CEO: We are confident in our company and where we are going »

Tech Data CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

18:34
09/18/19
09/18
18:34
09/18/19
18:34
Periodicals
AT&T, Dish not in discussions over DirecTV deal, Reuters reports »

AT&T (T) and Dish…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

AGCO

Agco

$76.04

-0.16 (-0.21%)

18:30
09/18/19
09/18
18:30
09/18/19
18:30
Hot Stocks
Agco CEO: We are on schedule in the U.S. »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.63

-0.31 (-2.08%)

18:22
09/18/19
09/18
18:22
09/18/19
18:22
Periodicals
Petrobras raises gasoline, diesel prices in wake of Saudi attacks, Reuters says »

Petrobras has boosted the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$123.69

-0.28 (-0.23%)

18:01
09/18/19
09/18
18:01
09/18/19
18:01
Hot Stocks
Celanese increases Vinyl Acetate Monomer price in EMEA by EUR50/MT »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

$68.57

0.48 (0.70%)

18:00
09/18/19
09/18
18:00
09/18/19
18:00
Hot Stocks
SunTrust lowers prime lending rate to 5% from 5.25% »

Following the Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBS

Webster Financial

$48.84

0.43 (0.89%)

17:53
09/18/19
09/18
17:53
09/18/19
17:53
Hot Stocks
Webster Financial lowers prime lending rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 13

    Nov

HSBC

HSBC

$38.19

-0.1 (-0.26%)

17:52
09/18/19
09/18
17:52
09/18/19
17:52
Hot Stocks
HSBC decreases prime lending rate to 5% from 5.25% »

HSBC Bank USA and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

HES

Hess Corp.

$66.91

-0.92 (-1.36%)

17:50
09/18/19
09/18
17:50
09/18/19
17:50
Hot Stocks
Hess Corp. COO sells 17,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

CSCO

Cisco

$49.32

-0.1 (-0.20%)

, DDOG

Datadog

$0.00

(0.00%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Periodicals
Cisco approached Datadog with $7B+ takeover bid, Bloomberg says »

Cisco (CSCO) approached…

CSCO

Cisco

$49.32

-0.1 (-0.20%)

DDOG

Datadog

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.